TFF Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing technology platform. Co. has two product candidates under development, TFF Voriconazole Inhalation Powder and TFF Tacrolimus Inhalation Powder. Co. is engaged in the analysis and testing of dry powder formulations of several drugs and vaccines through parenteral, topical, ocular, pulmonary and nasal applications through feasibility studies and material transfer agreements with U.S. and international pharmaceutical companies and certain government agencies. The TFFP average annual return since 2019 is shown above.
The Average Annual Return on the TFFP average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TFFP average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TFFP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|